226 related articles for article (PubMed ID: 27284251)
1. Targeting gastrointestinal stromal tumors: the role of regorafenib.
Schroeder B; Li Z; Cranmer LD; Jones RL; Pollack SM
Onco Targets Ther; 2016; 9():3009-16. PubMed ID: 27284251
[TBL] [Abstract][Full Text] [Related]
2. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
Crona DJ; Keisler MD; Walko CM
Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
[TBL] [Abstract][Full Text] [Related]
3. Durable tumor regression in highly refractory metastatic
Schroeder BA; Kohli K; O'Malley RB; Kim TS; Jones RL; Pierce RH; Pollack SM
Oncoimmunology; 2020; 9(1):1710064. PubMed ID: 32002307
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
Nishida T; Doi T; Naito Y
Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.
Ben-Ami E; Barysauskas CM; von Mehren M; Heinrich MC; Corless CL; Butrynski JE; Morgan JA; Wagner AJ; Choy E; Yap JT; Van den Abbeele AD; Solomon SM; Fletcher JA; Demetri GD; George S
Ann Oncol; 2016 Sep; 27(9):1794-9. PubMed ID: 27371698
[TBL] [Abstract][Full Text] [Related]
6. Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib.
Vincenzi B; Nannini M; Badalamenti G; Grignani G; Fumagalli E; Gasperoni S; D'Ambrosio L; Incorvaia L; Stellato M; Spalato Ceruso M; Napolitano A; Valeri S; Santini D; Tonini G; Casali PG; Dei Tos AP; Pantaleo MA
Ther Adv Med Oncol; 2018; 10():1758835918794623. PubMed ID: 30181783
[TBL] [Abstract][Full Text] [Related]
7. The safety of regorafenib for the treatment of gastrointestinal stromal tumors.
Rutkowski P; Stępniak J
Expert Opin Drug Saf; 2016 Jan; 15(1):105-16. PubMed ID: 26651387
[TBL] [Abstract][Full Text] [Related]
8. Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors.
Demetri GD
Semin Oncol; 2011 Apr; 38 Suppl 1():S10-9. PubMed ID: 21419931
[TBL] [Abstract][Full Text] [Related]
9. The Role of Surgery in Metastatic Gastrointestinal Stromal Tumors.
Keung EZ; Fairweather M; Raut CP
Curr Treat Options Oncol; 2016 Feb; 17(2):8. PubMed ID: 26820287
[TBL] [Abstract][Full Text] [Related]
10. Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib.
Kim JJ; Ryu MH; Yoo C; Beck MY; Ma JE; Kang YK
Oncologist; 2019 Nov; 24(11):e1212-e1218. PubMed ID: 31036770
[TBL] [Abstract][Full Text] [Related]
11. Ripretinib in combination with tyrosine kinase inhibitor as a late-line treatment option for refractory gastrointestinal stromal tumors: two case reports and literature review.
Zhang Y; Huang Z
Front Pharmacol; 2023; 14():1122885. PubMed ID: 37288114
[No Abstract] [Full Text] [Related]
12. Surgery for metastatic gastrointestinal stromal tumor: to whom and how to?
Kikuchi H; Hiramatsu Y; Kamiya K; Morita Y; Sakaguchi T; Konno H; Takeuchi H
Transl Gastroenterol Hepatol; 2018; 3():14. PubMed ID: 29682621
[TBL] [Abstract][Full Text] [Related]
13. Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Registry.
Call JW; Wang Y; Montoya D; Scherzer NJ; Heinrich MC
Clin Sarcoma Res; 2019; 9():4. PubMed ID: 30984366
[TBL] [Abstract][Full Text] [Related]
14. The BRAF Status May Predict Response to Sorafenib in Gastrointestinal Stromal Tumors Resistant to Imatinib, Sunitinib, and Regorafenib: Case Series and Review of the Literature.
Franck C; Rosania R; Franke S; Haybaeck J; Canbay A; Venerito M
Digestion; 2019; 99(2):179-184. PubMed ID: 30179868
[TBL] [Abstract][Full Text] [Related]
15. Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.
Serrano C; George S; Valverde C; Olivares D; García-Valverde A; Suárez C; Morales-Barrera R; Carles J
Target Oncol; 2017 Jun; 12(3):277-288. PubMed ID: 28478525
[TBL] [Abstract][Full Text] [Related]
16. 2023 GEIS Guidelines for gastrointestinal stromal tumors.
Serrano C; Martín-Broto J; Asencio-Pascual JM; López-Guerrero JA; Rubió-Casadevall J; Bagué S; García-Del-Muro X; Fernández-Hernández JÁ; Herrero L; López-Pousa A; Poveda A; Martínez-Marín V
Ther Adv Med Oncol; 2023; 15():17588359231192388. PubMed ID: 37655207
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17.
Yeh CN; Chen MH; Chen YY; Yang CY; Yen CC; Tzen CY; Chen LT; Chen JS
Oncotarget; 2017 Jul; 8(27):44121-44130. PubMed ID: 28487491
[TBL] [Abstract][Full Text] [Related]
18. An Unusual Case of Central Retinal Vein Occlusion and Review of the Toxicity Profile of Regorafenib in GIST Patients.
Schvartsman G; Wagner MJ; Zobniw CM; Trinh VA; Patel S; Somaiah N
Curr Oncol Rep; 2016 Aug; 18(8):49. PubMed ID: 27319943
[TBL] [Abstract][Full Text] [Related]
19. Regorafenib in gastrointestinal stromal tumors: clinical evidence and place in therapy.
Ferraro D; Zalcberg J
Ther Adv Med Oncol; 2014 Sep; 6(5):222-8. PubMed ID: 25342989
[TBL] [Abstract][Full Text] [Related]
20. Establishment and characterization of patient-derived xenograft models of gastrointestinal stromal tumor resistant to standard tyrosine kinase inhibitors.
Na YS; Ryu MH; Yoo C; Lee JK; Park JM; Lee CW; Lee SY; Shin YK; Ku JL; Ahn SM; Kang YK
Oncotarget; 2017 Sep; 8(44):76712-76721. PubMed ID: 29100343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]